Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Preclinical Development: Overview01:28

Preclinical Development: Overview

5.7K
Preclinical development consists of a series of tests that ensure the safety and efficacy of a new therapeutic compound before it is tested in humans. There are four main phases to this process. First, safety pharmacology tests are conducted to ensure the drug does not produce any acutely harmful effects. These tests examine parameters such as bronchoconstriction, cardiac dysrhythmias, blood pressure changes, and ataxia. Next, preliminary toxicological testing is performed to determine the...
5.7K
Clinical Trials: Overview01:11

Clinical Trials: Overview

4.5K
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
4.5K
Drug Discovery: Overview01:26

Drug Discovery: Overview

10.9K
Drug discovery is a multifaceted process involving extensive screening, testing, and optimization of lead compounds to identify potential new drugs for therapeutic use. It combines several approaches, including screening large numbers of natural products, chemical modification of known active molecules, identification of new drug targets, and rational design based on biological mechanisms and drug-receptor structure. These approaches are carried out in both academic research laboratories and...
10.9K
Drug Administration and Therapy Phases: Overview01:26

Drug Administration and Therapy Phases: Overview

1.1K
Drugs, the chemical agents used in diagnosing, treating, or preventing diseases, undergo a four-phase process of development: pharmaceutic, pharmacokinetics, pharmacodynamics, and therapeutic.
The pharmaceutical phase focuses on leveraging the physicochemical properties of the drug to design and manufacture an effective product. Variants include orally administered tablets or capsules, topical creams or ointments, and parenteral-delivery solutions or emulsions.
The pharmacokinetic phase...
1.1K
In Vitro Drug Release Testing: Overview, Development and Validation01:10

In Vitro Drug Release Testing: Overview, Development and Validation

279
In vitro dissolution and drug release tests assess how quickly and how much of a drug is released from its dosage form into an aqueous medium under standardized laboratory conditions. These tests are essential tools in pharmaceutical development and quality assurance, offering insight into the drug's performance before clinical use.During formulation development, dissolution testing identifies incomplete or inconsistent drug release issues. It also supports decisions on selecting the optimal...
279
Drug Regulation01:25

Drug Regulation

2.7K
Drug regulation encompasses the management of drug usage by evaluating its safety and efficacy through assessments conducted by regulatory authorities. Regrettably, the history of drug regulation is marred by several catastrophic events. One such incident is the Elixir Sulfanilamide tragedy, in which the toxic compound diethyl glycol was included in a sweet-tasting medication, leading to numerous fatalities. This event prompted the enactment of the Food, Drug, and Cosmetic Act in 1938. Under...
2.7K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Comorbidity sequence, sex, and APOE-genotype forecast Alzheimer's disease diagnosis.

Frontiers in medicine·2026
Same author

APOE4 accelerates menopause-associated brain metabolic shift and disrupts bioenergetic adaptation.

Frontiers in aging neuroscience·2026
Same author

Anti-inflammatory and immunomodulatory therapies are associated with reduced risk of age-associated neurodegenerative diseases: impact of sex and treatment duration.

Frontiers in aging neuroscience·2026
Same author

Addition of humanized APP to humanized <i>APOE</i> mouse model reduces brain size and increases the ratio of cortical representation.

bioRxiv : the preprint server for biology·2026
Same author

Meta analysis of glucose metabolism across Alzheimer's, Parkinson's and ALS Reveals emergence of adaptive brain glucometabolic responses and associated neurological functional profiles.

medRxiv : the preprint server for health sciences·2026
Same author

Premenopausal bilateral oophorectomy leads to steeper declines in gray matter volume and alterations in perfusion and brain bioenergetics.

Scientific reports·2026

Related Experiment Video

Updated: Jan 7, 2026

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System
05:10

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System

Published on: December 11, 2016

10.1K

Drug Development.

Helena Cortes-Flores1, Georgina Torrandell-Haro1, Roberta Diaz Brinton1

  • 1University of Arizona, Tucson, AZ, USA.

Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association
|December 26, 2025
PubMed
Summary

Anti-inflammatory treatments (aIT) significantly reduced Alzheimer's Disease (AD) risk, especially with long-term use and specific drug classes like COX inhibitors. Age and treatment duration were key factors in this neuroinflammation-related benefit.

Area of Science:

  • Neuroscience
  • Pharmacology
  • Gerontology

Background:

  • Inflammation is a key factor in neurodegenerative diseases like Alzheimer's Disease (AD), with inflammatory processes evident even in early stages.
  • The precise role of anti-inflammatory treatments (aIT) in mitigating AD risk remains an area requiring further investigation.
  • This study aimed to assess the impact of aIT on AD incidence and to characterize patient responses to these treatments.

Purpose of the Study:

  • To evaluate the effect of anti-inflammatory treatments (aIT) on the incidence of Alzheimer's Disease (AD).
  • To identify and characterize patient subgroups who developed AD (non-responders) versus those who did not (responders) after aIT exposure.
  • To explore factors influencing the relationship between aIT and AD risk, including drug class, treatment duration, and patient demographics.

More Related Videos

In Vitro Three-Dimensional Sprouting Assay of Angiogenesis Using Mouse Embryonic Stem Cells for Vascular Disease Modeling and Drug Testing
08:04

In Vitro Three-Dimensional Sprouting Assay of Angiogenesis Using Mouse Embryonic Stem Cells for Vascular Disease Modeling and Drug Testing

Published on: May 11, 2021

3.3K
Developmental Toxicity Assay Based on Real-Time Monitoring of Fibroblast Growth Factor Signal Disruption in Human Induced Pluripotent Stem Cells
05:45

Developmental Toxicity Assay Based on Real-Time Monitoring of Fibroblast Growth Factor Signal Disruption in Human Induced Pluripotent Stem Cells

Published on: October 10, 2025

451

Related Experiment Videos

Last Updated: Jan 7, 2026

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System
05:10

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System

Published on: December 11, 2016

10.1K
In Vitro Three-Dimensional Sprouting Assay of Angiogenesis Using Mouse Embryonic Stem Cells for Vascular Disease Modeling and Drug Testing
08:04

In Vitro Three-Dimensional Sprouting Assay of Angiogenesis Using Mouse Embryonic Stem Cells for Vascular Disease Modeling and Drug Testing

Published on: May 11, 2021

3.3K
Developmental Toxicity Assay Based on Real-Time Monitoring of Fibroblast Growth Factor Signal Disruption in Human Induced Pluripotent Stem Cells
05:45

Developmental Toxicity Assay Based on Real-Time Monitoring of Fibroblast Growth Factor Signal Disruption in Human Induced Pluripotent Stem Cells

Published on: October 10, 2025

451

Main Methods:

  • Retrospective analysis of an insurance claims dataset involving patients aged 60 and older.
  • Inclusion of oral corticosteroids, non-selective COX inhibitors, and COX-2 selective inhibitors as studied aIT.
  • Application of propensity score matching to control for age, gender, Charlson Comorbidity Index (CCI), and other comorbidities in a cohort of 225,742 patients.

Main Results:

  • Anti-inflammatory treatment (aIT) use was associated with a significant reduction in AD diagnosis risk (RR: 0.35 [0.33-0.37], P<.001).
  • The risk reduction was more pronounced with aIT use of at least one year, with COX inhibitors showing greater efficacy than corticosteroids.
  • Patients aged 75-79 and those with longer treatment durations (≥6 years) experienced the most substantial risk reduction, irrespective of gender.

Conclusions:

  • The study provides evidence supporting an association between anti-inflammatory treatments (aIT) and a reduced risk of Alzheimer's Disease (AD).
  • Patient age, duration of aIT exposure, and specific drug classes (e.g., COX inhibitors) are critical determinants of AD risk reduction.
  • These findings offer valuable insights for developing future interventions targeting neuroinflammation to prevent AD.